SINTX Technologies and NED Medical Partner to Advance Cutting-Edge Ceramic Microsphere Medical Devices for Cancer Treatment
SINTX Technologies (NASDAQ: SINT) has signed a Joint Development Agreement with NED Medical to develop advanced ceramic-based microspheres for cancer treatment. The collaboration focuses on manufacturing microspheres containing Yttrium-90 radioisotope for transarterial radioembolization (TARE) treatment of hepatocellular carcinoma. The engineered microspheres, known as CombiSphere, feature unique properties including radiopacity and porosity, allowing for targeted chemotherapy and combination therapies. SINTX will support NED Medical's pre-clinical testing needs and transition the microsphere process from R&D to pilot production.
SINTX Technologies (NASDAQ: SINT) ha firmato un Accordo di Sviluppo Congiunto con NED Medical per sviluppare microsfere avanzate a base ceramica per il trattamento del cancro. La collaborazione si concentra sulla produzione di microsfere contenenti isotopo radioattivo Yttrium-90 per il trattamento di radioembolizzazione transarteriosa (TARE) del carcinoma epatocellulare. Le microsfere ingegnerizzate, conosciute come CombiSphere, presentano proprietà uniche tra cui radiopacità e porosità, consentendo una chemioterapia mirata e terapie combinate. SINTX supporterà le esigenze di test preclinici di NED Medical e gestirà la transizione del processo delle microsfere dalla ricerca e sviluppo alla produzione pilota.
SINTX Technologies (NASDAQ: SINT) ha firmado un Acuerdo de Desarrollo Conjunto con NED Medical para desarrollar microsferas avanzadas basadas en cerámica para el tratamiento del cáncer. La colaboración se centra en la fabricación de microsferas que contienen el radioisótopo Yttrium-90 para el tratamiento de radioembolización transarterial (TARE) del carcinoma hepatocelular. Las microsferas diseñadas, conocidas como CombiSphere, presentan propiedades únicas que incluyen radiopacidad y porosidad, lo que permite quimioterapia dirigida y terapias combinadas. SINTX apoyará las necesidades de pruebas preclínicas de NED Medical y hará la transición del proceso de microsferas de I+D a producción piloto.
SINTX Technologies (NASDAQ: SINT)는 NED Medical과 협력하여 암 치료를 위한 첨단 세라믹 기반의 마이크로스피어 개발을 위한 공동 개발 협정에 서명했습니다. 이 협력은 간세포암의 치료를 위한 경동맥 내 방사성 색전술(TARE)을 위해 Yttrium-90 방사능 동위원소를 포함하는 마이크로스피어 제조에 중점을 두고 있습니다. CombiSphere로 알려진 엔지니어링된 마이크로스피어는 방사선 투과성과 다공성을 포함한 독특한 특성을 지니며, 이를 통해 표적 화학요법 및 병합 요법이 가능합니다. SINTX는 NED Medical의 전임상 시험 요구를 지원하고 마이크로스피어 프로세스를 연구개발에서 시범 생산으로 전환할 것입니다.
SINTX Technologies (NASDAQ: SINT) a signé un Accord de Développement Conjoint avec NED Medical pour développer des microsphères avancées à base de céramique pour le traitement du cancer. La collaboration se concentre sur la fabrication de microsphères contenant l'isotope radioactif Yttrium-90 pour le traitement par radioembolie transartérielle (TARE) du carcinome hépatocellulaire. Les microsphères conçues, connues sous le nom de CombiSphere, présentent des propriétés uniques, notamment la radiopacité et la porosité, permettant une chimiothérapie ciblée et des thérapies combinées. SINTX soutiendra les besoins de tests précliniques de NED Medical et effectuera la transition du processus de microsphères de la recherche et développement à la production pilote.
SINTX Technologies (NASDAQ: SINT) hat eine gemeinsame Entwicklungsvereinbarung mit NED Medical unterzeichnet, um fortschrittliche keramikbasierte Mikrosphären zur Bekämpfung von Krebs zu entwickeln. Die Zusammenarbeit konzentriert sich auf die Herstellung von Mikrosphären, die das radioaktive Isotop Yttrium-90 für die transarterielle Radioembolisierung (TARE) zur Behandlung des hepatozellulären Karzinoms enthalten. Die entwickelten Mikrosphären, bekannt als CombiSphere, besitzen einzigartige Eigenschaften wie Radiopazität und Porosität, die eine gezielte Chemotherapie und Kombinationstherapien ermöglichen. SINTX wird NED Medicals Bedürfnisse im Bereich der vorklinischen Tests unterstützen und den Prozess der Mikrosphären von der Forschung und Entwicklung in die Pilotproduktion überführen.
- Strategic expansion into high-growth radio therapeutics market
- Successful manufacturing feasibility demonstration of Yttrium-90 microspheres
- Development of unique CombiSphere technology with dual radiopaque and radiation-emitting properties
- None.
Insights
The partnership between SINTX and NED Medical represents a significant advancement in cancer treatment technology. Their CombiSphere microspheres combine two critical features - radiopacity and radiation emission - in a single particle, which is a notable technical achievement. The ceramic-based microspheres' density matching red blood cells suggests improved delivery characteristics compared to existing solutions.
The technology's dual functionality of Yttrium-90 radioisotope incorporation and potential for targeted chemotherapy delivery through engineered porosity positions this development favorably in the
However, investors should note that this is still in pre-clinical testing phase. While the technology shows promise, regulatory approval and commercialization timelines remain uncertain. For a micro-cap company like SINTX, successful development could be transformative, but significant capital requirements for clinical trials and regulatory submissions may necessitate future funding rounds.
This JDA strategically positions SINTX in the rapidly growing radiotherapeutics market. The company's transition from R&D to pilot production represents a important step toward commercialization. The partnership structure allows SINTX to leverage its ceramic expertise while sharing development costs and risks with NED Medical.
The addition of SINTX's CTO to NED Medical's Scientific Advisory Board strengthens the partnership and suggests long-term collaboration potential. For investors, this validates SINTX's technical capabilities and could lead to additional partnerships in the medical device sector.
Given SINTX's current
Salt Lake City, UT, Nov. 21, 2024 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), an advanced ceramics company that develops and commercializes materials, components, and technologies for medical and technical applications, announces the signing of a Joint Development Agreement (JDA) with NED Medical Inc., an innovative developer of oncology embolization therapy technologies. This collaboration aims to accelerate the development of advanced ceramic-based microspheres, a groundbreaking advancement in radiotherapeutic applications.
The partnership will see SINTX leverage its expertise in ceramic manufacturing to support NED medical’s pre-clinical testing needs and perform the necessary process validation and verification activities to transition the microsphere process from the R&D scale to pilot production. “Our successful manufacturing feasibility collaboration with NED Medical demonstrated that SINTX could manufacture novel ceramic-based microspheres containing the Yttrium-90 radioisotope that met NED Medical’s preliminary specifications for a transarterial radioembolization (TARE) device for treatment of hepatocellular carcinoma. Further, these engineered microspheres contain porosity, allowing their future adaptation for targeted chemotherapy and combination therapies,” said Dr. Ryan Bock, CTO of SINTX Technologies. During this JDA, SINTX and NED Medical will collaborate closely, optimizing microsphere production, finalizing characterization and safety assessments, and producing microspheres needed to obtain pre-clinical data to be used as part of a device clearance submission.
“We are excited to partner with NED Medical to develop next generation radiotherapeutic solutions that may have a transformative impact on cancer treatment,” said Eric K. Olson, CEO of SINTX Technologies. “This JDA underscores our commitment to advancing cutting-edge solutions that leverage our unique ceramic technology, which holds the potential to reshape the landscape of oncological therapies.”
“SINTX’s expertise in advanced ceramic processing has facilitated the development of CombiSphere, a next generation, radio-labeled microsphere with differentiated properties, including radiopacity to facilitate new dosimetry modalities and a unique physical structure that allows high per-particle radiation activity at a density similar to red blood cells,” said Richard Yazebeck, President, CEO, and Co-Founder of NED Medical. “Equally exciting, and only achievable because of the material composition and manufacturing process, is that every microsphere in a dose is both radiopaque and radiation-emitting.”
“Our partnership and collaboration with SINTX has transformed the trajectory of NED Medical and has positioned us to provide a unique solution to the clinical community. In addition to the announcement of our partnership, we are excited to welcome Ryan Bock, PhD, to our world-class Scientific Advisory Board (SAB). Dr. Bock is the CTO at SINTX and has played a pivotal role in the development of our R&D prototypes. Dr. Bock will join his peers on our SAB to advise and help direct the clinical development of CombiSphere.”
Investor Highlights:
- Strategic Expansion: This partnership highlights SINTX’s expansion into the high-growth field of radio therapeutics, a market projected to see substantial growth over the coming years.
- Innovative Technology: The use of SINTX’s proprietary ceramic microsphere technology is expected to optimize dosing and enhance treatment precision to improve patient outcomes, positioning SINTX as a front-runner in the field of targeted radio-therapeutic devices.
- Robust Pipeline: The agreement paves the way for potential future collaborations, including scaling production, further testing to meet regulatory requirements, and expanded indications within the oncology and musculoskeletal spaces.
Through this collaboration, SINTX aims to unlock new revenue opportunities and strengthen its position in the medical device sector, making it an attractive prospect for current and potential investors.
For more information, please visit www.sintx.com
About SINTX Technologies, Inc.
SINTX Technologies is an advanced ceramics company that develops and commercializes materials, components, and technologies for medical and technical applications. SINTX is a global leader in the research, development, and manufacturing of silicon nitride, and its products have been implanted in humans since 2008. Over the past several years, SINTX has utilized strategic acquisitions and alliances to enter new markets. The Company has manufacturing and R&D facilities in Utah and Maryland. For more information on SINTX Technologies or its materials platform, visit www.sintx.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (“PSLRA”) that are subject to a number of risks and uncertainties. Forward-looking statements can be identified by words such as: "anticipate," "believe," "project," "estimate," "expect," "strategy,” "future," "likely," "may," "should," "will" and similar references to future periods. Examples of forward-looking statements include, among others, statements we make regarding advancement of ceramic technologies and exploring new avenues for growth and innovation, and the potential to pursue growth opportunities and explore strategic opportunities.
Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management’s current estimates, projections, expectations and beliefs. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, difficulty in commercializing ceramic technologies and development of new product opportunities. A discussion of other risks and uncertainties that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements can be found in SINTX’s Risk Factors disclosure in its Annual Report on Form 10-K, filed with the SEC on March 27, 2024, and in SINTX’s other filings with the SEC. SINTX undertakes no obligation to publicly revise or update the forward-looking statements to reflect events or circumstances that arise after the date of this report, except as required by law.
Business and Media Inquiries for SINTX:
SINTX Technologies
801.839.3502
IR@sintx.com
FAQ
What is the purpose of SINTX Technologies' partnership with NED Medical?
What are the key features of SINTX's CombiSphere technology?
How will SINTX Technologies (SINT) support NED Medical in this collaboration?
